Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | UNK | — |
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | UNK | — |
that area stills burns at least once a week or more; that area stills itch at least once a week or more; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site burning in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis. Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine and Shingles vaccine, the patient experienced injection site burning (Verbatim: that area stills burns at least once a week or more) and injection site itching (Verbatim: that area stills itch at least once a week or more). The outcome of the injection site burning and injection site itching were not resolved. It was unknown if the reporter considered the injection site burning and injection site itching to be related to Shingles vaccine and Shingles vaccine. It was unknown if the company considered the injection site burning and injection site itching to be related to Shingles vaccine and Shingles vaccine. Additional Information: GSK Receipt Date: 22-MAR-2025 This case was reported by a patient via interactive digital media. The patient had the shot and a booster and that area stills burns and itch at least once a week or more.